−3.15USD
−112.64 MUSD
12.60 MUSD
28.54 M
About iTeos Therapeutics, Inc.
Sector
Industry
CEO
Michel Detheux
Website
Headquarters
Watertown
Employees (FY)
157
Founded
2012
FIGI
BBG00VPNFSJ5
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ITOS is 10.99 USD — it has increased by 1.85% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange iTeos Therapeutics, Inc. stocks are traded under the ticker ITOS.
iTeos Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
ITOS stock is 3.16% volatile and has beta coefficient of 1.58. Check out the list of the most volatile stocks — is iTeos Therapeutics, Inc. there?
ITOS earnings for the last quarter are −0.90 USD per share, whereas the estimation was −1.16 USD resulting in a 22.68% surprise. The estimated earnings for the next quarter are −1.03 USD per share. See more details about iTeos Therapeutics, Inc. earnings.
iTeos Therapeutics, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 12.47 M USD.
Yes, you can track iTeos Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ITOS stock has fallen by 5.99% compared to the previous week, the month change is a 3.60% fall, over the last year iTeos Therapeutics, Inc. has showed a 20.07% decrease.
ITOS net income for the last quarter is −30.55 M USD, while the quarter before that showed −32.24 M USD of net income which accounts for 5.24% change. Track more iTeos Therapeutics, Inc. financial stats to get the full picture.
Today iTeos Therapeutics, Inc. has the market capitalization of 386.75 M, it has decreased by 1.61% over the last week.
No, ITOS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ITOS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade iTeos Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 157.00 employees. See our rating of the largest employees — is iTeos Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So iTeos Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating iTeos Therapeutics, Inc. stock shows the sell signal. See more of iTeos Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on iTeos Therapeutics, Inc. future price: according to them, ITOS price has a max estimate of 47.00 USD and a min estimate of 18.00 USD. Read a more detailed iTeos Therapeutics, Inc. forecast: see what analysts think of iTeos Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. iTeos Therapeutics, Inc. EBITDA is −150.10 M USD, and current EBITDA margin is −1.19 K%. See more stats in iTeos Therapeutics, Inc. financial statements.